Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial.
James, N Pirrie, S Pope, A Barton, D Andronis, L Goranitis, I Collins, S Daunton, A McLaren, D O'Sullivan, J
James, N
Pirrie, S
Pope, A
Barton, D
Andronis, L
Goranitis, I
Collins, S
Daunton, A
McLaren, D
O'Sullivan, J
Citations
Altmetric:
Abstract
Bony metastatic castrate-refractory prostate cancer (CRPC) has a poor prognosis and high morbidity. Zoledronic acid (ZA) is commonly combined with docetaxel in practice but lacks evidence that combining is effective, and strontium-89 (Sr89) is generally used palliatively in patients unfit for chemotherapy. Phase 2 analysis of the TRAPEZE trial confirmed combining the agents was safe and feasible, and the objectives of phase 3 include assessment of the treatments on survival.
Description
Date
2016-01-21
Publisher
Collections
Keywords
Type
Article
Citation
Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE randomized clinical trial.. 2016: JAMA Oncol